| Literature DB >> 34293453 |
Guillaume Miltgen1, Maxime Bour2, Jérôme Allyn3, Nicolas Allou3, Thibaut Vedani4, Jean-Baptiste Vuillemenot5, Pauline Triponney2, Olivier Martinet6, Nathalie Lugagne7, Thierry Benoit-Cattin8, Laurent Dortet9, Aurélien Birer10, Marie-Christine Jaffar-Bandjee4, Olivier Belmonte4, Patrick Plésiat5, Anaïs Potron11.
Abstract
Dual resistance to colistin and carbapenems is a milestone reached by certain extensively-drug resistant (XDR) Gram-negative bacteria. This study describes the first outbreak of XDR colistin- and carbapenem-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii (CCRAB) in the European overseas territory of Reunion Island (France, Indian Ocean). Between April 2019 and June 2020, 13 patients admitted to the University Hospital of Reunion Island were involved in the outbreak, of whom eight were infected and six died. The first case was traced to a medical evacuation from Mayotte Island (Comoros archipelago). An epidemiological link could be established for 11 patients. All of the collected CCRAB isolates showed the same resistance profile and co-produced intrinsic β-lactamases OXA-69 and ADC-191, together with acquired carbapenem-hydrolysing β-lactamases OXA-23 and NDM-1. A mutation likely involved in colistin resistance was detected in the two-component system PmrAB (D82N in PmrA). All of the isolates were found to belong to STPas1/STOx231 clonal complex and were phylogenetically indistinguishable. Their further characterization by whole-genome sequence analyses (whole-genome multi-locus sequence typing, single nucleotide polymorphisms) provided hints about the transmission pathways. This study pleads for strict application of control and prevention measures in institutions where the risk of imported XDR bacteria is high.Entities:
Keywords: Acinetobacter baumannii; Colistin and carbapenem resistance; Extensively drug-resistant; Indian Ocean; Outbreak; Reunion Island
Mesh:
Substances:
Year: 2021 PMID: 34293453 DOI: 10.1016/j.ijantimicag.2021.106402
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN: 0924-8579 Impact factor: 5.283